Browse > Article

HER-2/neu Amplification Determined by Real-Time Quantitative PCR and Its Association with Clinical Outcome of Breast Cancer in Thailand  

Chariyalertsak, Sunanta (Research Division, National Cancer Institute)
Purisa, Wichai (Research Division, National Cancer Institute)
Vinyuvat, Songkhun (Institute of Pathology)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.12, no.7, 2011 , pp. 1703-1706 More about this Journal
Abstract
HER-2/neu has been found to be amplified or overexpressed in about 20-30% of breast cancers, in association with negative prognosticators and shortened survival. Determination of HER-2/neu status in breast-cancer patients, to select for adjuvant treatment with trastuzumab, is becoming standard breast-cancer clinical practice. This study aimed to investigate HER-2/neu status in breast-cancer by real-time quantitative polymerase chain reaction (PCR), allowing accurate and precise quantification of HER-2/neu amplification in tumor tissues. We evaluated 112 breast-cancer samples, of which 42 (37.5%) had HER-2/neu amplification. After a mean follow-up period of 71 months, HER-2/neu amplification was found to be significantly associated with increased risk of death (HR = 6.367, 95% CI = 1.787-22.684), even after adjusting for age, clinical stage, tumor size, lymph-node status, and histologic grade. These findings support a negative prognostic role for HER-2/neu in breast-cancer survival. We suggest that real-time quantitative PCR analysis of HER-2/neu amplification represents an alternative technique for establishing HER-2/neu status in routine clinical practice.
Keywords
HER-2/neu gene; realtime quantitative PCR; breast cancer;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Akiyama T, Sudo C, Ogawara H, et al (1986). The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science, 232, 1644-6.   DOI
2 Borg A, Baldetorp B, Fernö M, et al (1994). ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett, 81, 137-44.   DOI   ScienceOn
3 Carlomagno C, Perrone F, Gallo C, et al (1996). c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol, 14, 2702-8.   DOI
4 Carr JA, Havstad S, Zarbo RJ, et al (2000). The association of HER-2/neu amplification with breast cancer recurrence. Arch Surg, 135, 1469-74.   DOI   ScienceOn
5 Gibson UE, Heid CA, Williams PM (1996). A novel method for real time quantitative RT-PCR. Genome Res, 6, 995-1001.   DOI   ScienceOn
6 Gjerdrum LM, Sorensen BS, Kjeldsen E, et al (2004). Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysis. J Mol Diagn, 6, 42-51.   DOI   ScienceOn
7 Gusterson BA, Gelber RD, Goldhirsch A, et al (1992). Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol, 10, 1049-56.   DOI
8 Heid CA, Stevens J, Livak KJ, et al (1996). Real time quantitative PCR. Genome Res, 6, 986-94.   DOI   ScienceOn
9 Kim YR, Choi JR, Song KS, et al (2002). Evaluation of HER2/ neu status by real-time quantitative PCR in breast cancer. Yonsei Med J, 43, 335-40.   DOI
10 Konigshoff M, Wilhelm J, Bohle RM, et al (2003). HER-2/ neu gene copy number quantified by real-time PCR: comparison of gene amplification, heterozygosity, and immunohistochemical status in breast cancer tissue. Clin Chem, 49, 219-29.   DOI   ScienceOn
11 Kulka J, Tokes AM, Kaposi-Novak P, et al (2006). Detection of HER-2/neu gene amplification in breast carcinomas using quantitative real-time PCR - a comparison with immunohistochemical and FISH results. Pathol Oncol Res, 12, 197-204.   DOI
12 Lehmann U, Kreipe H (2001). Real-time PCR analysis of DNA and RNA extracted from formalin-fixed and paraffinembedded biopsies. Methods, 25, 409-18.   DOI   ScienceOn
13 Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real- time quantitation PCR and the 2 (-Delta Delta C(T)) Method. Methods, 25, 402-8.   DOI   ScienceOn
14 Marmor MD, Skaria KB, Yarden Y (2004). Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys, 58, 903-13.   DOI   ScienceOn
15 Mayr D, Heim S, Weyrauch K, et al (2009). Chromogenic in situ hybridization for HER-2/neu-oncogene in breast cancer: comparison of a new dual-colour chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization. Histopathology, 55, 716-23.   DOI   ScienceOn
16 Muleris M, Almeida A, Malfoy B, et al (1997) Assignment of v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2) to human chromosome band 17q21.1 by in situ hybridization. Cytogenet Cell Genet, 76, 34-5.   DOI
17 Owens MA, Horten BC, Da Silva MM (2004). HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer, 5, 63-9.   DOI   ScienceOn
18 Peiro G, Aranda FI, Adrover E, et al (2007). Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node-negative breast carcinoma: Prognostic relevance. Hum Pathol, 38, 26-34.   DOI   ScienceOn
19 Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al (2005). Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, 353, 1659-72.   DOI   ScienceOn
20 Press MF, Bernstein L, Thomas PA, et al (1997). HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol, 15, 2894-904.   DOI
21 Quenel N, Wafflart J, Bonichon F, et al (1995). The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases. Breast Cancer Res Treat, 35, 283-91.   DOI   ScienceOn
22 Revillion F, Bonneterre J, Peyrat JP (1998). ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer, 34, 791-808.   DOI   ScienceOn
23 Ring BZ, Seitz RS, Beck R, et al (2006). Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol, 24, 3039-47.   DOI   ScienceOn
24 Riou G, Mathieu MC, Barrois M, et al (2001) c-erbB-2 (HER-2/ neu) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast-cancer patients. Int J Cancer, 95, 266-70.   DOI   ScienceOn
25 Romond EH, Perez EA, Bryant J, et al (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med, 353, 1673-84.   DOI   ScienceOn
26 Ross JS, Fletcher JA, Bloom KJ, et al (2004). Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics, 3, 379-98.   DOI   ScienceOn
27 Ross JS, Fletcher JA (1998). The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy. Oncologist, 3, 237-52.
28 Schechter AL, Stern DF, Vaidyanathan L, et al (1984). The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature, 312, 513-6.   DOI   ScienceOn
29 Slamon DJ, Clark GM, Wong SG, et al (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-82.   DOI
30 Slamon DJ, Godolphin W, Jones LA, et al (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244, 707-12.   DOI
31 Tuma RS (2005). Trastuzumab trials steal show at ASCO meeting. J Natl Cancer Inst, 97, 870-1.   DOI   ScienceOn
32 Slamon DJ, Leyland-Jones B, Shak S, et al (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344, 783-92.   DOI   ScienceOn
33 Smith I, Procter M, Gelber RD, et al ( 2007). HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet, 369, 29-36.   DOI   ScienceOn
34 Tetu B, Brisson J, Plante V, et al (1998) p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer. Mod Pathol, 11, 823-30.
35 van de Vijver M (2002). Emerging technologies for HER2 testing. Oncology, 63, 33-8.   DOI
36 Yarden Y (2001). Biology of HER2 and its importance in breast cancer. Oncology, 61, 1-13.
37 Yaziji H, Goldstein LC, Barry TS, et al (2004). HER-2 testing in breast cancer using parallel tissue-based methods. JAMA, 291, 1972-7.   DOI   ScienceOn